Nanomedicine-mediated regulated cell death in cancer immunotherapy

Yue Sun; Ting Lian; Qichao Huang; Yawei Chang; Yuan Li; Xiaoyu Guo; Weirong Kong; Yifang Yang; Kun Zhang; Pan Wang; Xiaobing Wang

doi:10.1016/j.jconrel.2023.10.032

Nanomedicine-mediated regulated cell death in cancer immunotherapy

J Control Release. 2023 Dec:364:174-194. doi: 10.1016/j.jconrel.2023.10.032. Epub 2023 Oct 27.

Authors

Yue Sun¹, Ting Lian², Qichao Huang³, Yawei Chang³, Yuan Li³, Xiaoyu Guo³, Weirong Kong³, Yifang Yang³, Kun Zhang³, Pan Wang⁴, Xiaobing Wang⁵

Affiliations

¹ National Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest China, The Key Laboratory of Medicinal Resources and Natural Pharmaceutical Chemistry, The Ministry of Education, College of Life Sciences, Shaanxi Normal University, Xi'an, Shaanxi 710119, China; The Xi'an key Laboratory of Pathogenic Microorganism and Tumor Immunity, Xi'an Medical University, Xi'an, Shaanxi 710021, China.
² Research Center for Prevention and Treatment of Respiratory Disease, School of Clinical Medicine, Xi'an Medical University, Xi'an, Shaanxi 710021, China.
³ National Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest China, The Key Laboratory of Medicinal Resources and Natural Pharmaceutical Chemistry, The Ministry of Education, College of Life Sciences, Shaanxi Normal University, Xi'an, Shaanxi 710119, China.
⁴ National Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest China, The Key Laboratory of Medicinal Resources and Natural Pharmaceutical Chemistry, The Ministry of Education, College of Life Sciences, Shaanxi Normal University, Xi'an, Shaanxi 710119, China. Electronic address: wangpan@snnu.edu.cn.
⁵ National Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest China, The Key Laboratory of Medicinal Resources and Natural Pharmaceutical Chemistry, The Ministry of Education, College of Life Sciences, Shaanxi Normal University, Xi'an, Shaanxi 710119, China. Electronic address: wangxiaobing@snnu.edu.cn.

PMID: 37871752
DOI: 10.1016/j.jconrel.2023.10.032

Abstract

Immunotherapy has attracted widespread attention in cancer treatment and has achieved considerable success in the clinical treatment of some tumors, but it has a low response rate in most tumors. To achieve sufficient activation of the immune response, significant efforts using nanotechnology have been made to enhance cancer immune response. In recent years, the induction of various regulated cell death (RCD) has emerged as a potential antitumor immuno-strategy, including processes related to apoptosis, autophagy, necroptosis, pyroptosis, ferroptosis, and cuproptosis. In particular, damage-associated molecular patterns (DAMPs) released from the damaged membrane of dying cells act as in situ adjuvants to trigger antigen-specific immune responses by the exposure of an increased antigenicity. Thus, RCD-based immunotherapy offers a new approach for enhancing cancer treatment efficacy. Furthermore, incorporation with multimodal auxiliary therapies in cell death-based immunotherapy can trigger stronger immune responses, resulting in more efficient therapeutic outcome. This review discusses different RCD modalities and summarizes recent nanotechnology-mediated RCDs in cancer immunotherapy.

Keywords: Anti-cancer immunotherapy; Immunogenic cell death; Nanomedicine; Regulated cell death.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Apoptosis
Humans
Immunotherapy / methods
Nanomedicine
Neoplasms* / drug therapy
Regulated Cell Death*